Determinants of newly diagnosed comorbidities among breast cancer survivors

详细信息    查看全文

• 作者：Nadia Obi (1) (4)
  Daniela Gornyk (1)
  Judith Heinz (1)
  Alina Vrieling (2) (3)
  Petra Seibold (2)
  Jenny Chang-Claude (2)
  Dieter Flesch-Janys (1)
  
• 关键词：Breast cancer survivors ; Comorbidity ; Hypertension ; Osteoporosis ; Aromatase inhibitor ; Trastuzumab
• 刊名：Journal of Cancer Survivorship
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：8
• 期：3
• 页码：384-393
• 全文大小：239 KB
• 参考文献：1. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society 2012.
  2. Cancer survival in England: Patients diagnosed 2005-009 and followed up to 2010. Office for National Statistics (ONS). London, 2011. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-239726#tab-all-tables. Accessed 9 Mar 2013.
  3. Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003;58(1):82-1.
  4. Girones R, Torregrosa D, Díaz-Beveridge R. Comorbidity, disability and geriatric syndromes in elderly breast cancer survivors. Results of a single-center experience. Crit Rev Oncol Hematol. 2010;73(3):236-5. CrossRef
  5. Rao AV, Demark-Wahnefried W. The older cancer survivor. Crit Rev Oncol Hematol. 2006;60(2):131-3. CrossRef
  6. Land LH, Dalton SO, Jorgensen TL, Ewertz M. Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol/Hematol. 2012;81(2):196-05. CrossRef
  7. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011;103(14):1101-1. CrossRef
  8. Newschaffer CJ, Bush TL, Penberthy LT. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol. 1997;50(6):725-3. CrossRef
  9. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003;98(9):1802-0. CrossRef
  10. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299-09. CrossRef
  11. Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol. 2012;60(24):2504-2. CrossRef
  12. Harlan LC, Klabunde CN, Ambs AH, et al. Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv. 2009;3(2):89-8. CrossRef
  13. Khan NF, Mant D, Carpenter L, Forman D, Rose PW. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer. 2011;105 Suppl 1:S29-7. CrossRef
  14. Flesch-Janys D, Slanger T, Mutschelknauss E, et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer. 2008;123(4):933-1. CrossRef
  15. Schmidt ME, Chang-Claude J, Vrieling A, et al. Association of pre-diagnosis physical activity with recurrence and mortality among women with breast cancer. Int J Cancer. 2013;133(6):1431-0. CrossRef
  16. De Laet C, Kanis JA, Oden A, et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330-. CrossRef
  17. Isidoro B, Lope V, Pedraz-Pingarron C, et al. Validation of obesity based on self-reported data in Spanish women participants in breast cancer screening programmes. BMC Public Health. 2011;11:960. CrossRef
  18. Spencer EA, Appleby PN, Davey GK, Key TJ. Validity of self-reported height and weight in 4808 EPIC-Oxford participants. Public Health Nutr. 2002;5(4):561-. CrossRef
  19. Li J, Siegrist J. Physical activity and risk of cardiovascular disease—a meta-analysis of prospective cohort studies. Int J Environ Res Public Health. 2012;9(2):391-07. CrossRef
  20. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol. 2009;20(8):1319-9. CrossRef
  21. Ligibel JA, James OA, Fisher M, Daniel GW, Winer EP, Keating NL. Risk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients. Breast Cancer Res Treat. 2012;131(2):589-7. CrossRef
  22. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2?years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005;23(22):5126-7. CrossRef
  23. Geisler J, Lonning PE. Impact of aromatase inhibitors on bone health in breast cancer patients. J Steroid Biochem Mol Biol. 2010;118(4-):294-.
  24. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. Lancet Oncol. 2012;13(3):275-4. CrossRef
  25. Arimidex, Tamoxifen, Alone or in Combination Trialists' Group, Buzdar A, Howell A, Cuzick J, Wale C, Distler W, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. The Lancet Oncology. 2006;7(8):633-3. CrossRef
  26. Mouridsen H, Keshaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007;25(36):5715-2. CrossRef
  27. McCaig F, Renshaw L, Williams L, et al. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2010;119(3):643-1. CrossRef
  28. Untch M, Jackisch C, Thomssen C, Nitz U, von Minkwitz G, Kaufmann M. Adjuvant treatment with trastuzumab in patients with breast cancer. Dtsch Arztebl. 2006;103(50):3406-0.
  29. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1?year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011;12(3):236-4. CrossRef
  30. Hysing J, Wist E. Cardiotoxic effects of trastuzumab. Tidsskr Nor Laegeforen. 2011;131(22):2239-1. CrossRef
  31. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300-1. CrossRef
  32. Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM et al. 2?years versus 1?year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. The Lancet, published online 18-7-2013.
  33. Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. JNCI. 2012;104(17):1293-05. CrossRef
  34. Romond EH, Jeong JH, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30(31):3792-. CrossRef
  35. Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer. 2012;118(8 Suppl):2270-. CrossRef
  36. Harris EER, Correa C, Hwang WT, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. J Clin Oncol. 2006;24(25):4100-. CrossRef
  37. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937-7. CrossRef
  38. Slanger T, Mutschelknauss E, Kropp S, Braendle W, Flesch-Janys D, Chang-Claude J. Test-retest reliability of self-reported reproductive and lifestyle data in the context of a German case-control study on breast cancer and postmenopausal hormone therapy. Ann Epidemiol. 2007;17(12):993-. CrossRef
  39. Silliman RA, Lash TL. Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients. Med Care. 1999;37(4):339-9. CrossRef
  40. Kriegsman DM, Penninx BW, van Eijk JT, Boeke AJ, Deeg DJ. Self-reports and general practitioner information on the presence of chronic diseases in community dwelling elderly. A study on the accuracy of patients-self-reports and on determinants of inaccuracy. J Clin Epidemiol. 1996;49(12):1407-7. CrossRef
  41. Fuchs J, Busch M, Lange C, Scheidt-Nave C. Prevalence and patterns of morbidity among adults in Germany. Results of the German telephone health interview survey German Health Update (GEDA) 2009. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012;55(4):576-6. CrossRef
  42. Moebus S, Hanisch J, Aidelsburger P, Bramlage P, Wasem J, Jockel KH. Impact of 4 different definitions used for the assessment of the prevalence of the metabolic syndrome in primary healthcare: the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol. 2007;6(1):22. CrossRef
  43. Garriguet D. Bone health: osteoporosis, calcium and vitamin D. Health Rep. 2011;22(3):7-4.
  
• 作者单位：Nadia Obi (1) (4)
  Daniela Gornyk (1)
  Judith Heinz (1)
  Alina Vrieling (2) (3)
  Petra Seibold (2)
  Jenny Chang-Claude (2)
  Dieter Flesch-Janys (1)
  
  1. University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
  4. Clinical Cancer Registry/Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany
  2. Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
  3. Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands
  
• ISSN：1932-2267

文摘

Purpose Comorbid conditions have become increasingly relevant for breast cancer care given the large numbers of long-term survivors. Our aim was to identify potential determinants associated with the development of comorbidities after breast cancer. Methods Self-reported comorbidities and lifestyle were assessed at recruitment and after a median follow up of 69.4?months from diagnosis in a population-based cohort of breast cancer cases aged 50 to 74?years at diagnosis (MARIEplus study). Tumor and therapy data were extracted from medical records. Determinants potentially associated with incident diagnoses of hypertension, cardiovascular diseases (CVD), and osteoporosis were assessed using multivariable Cox proportional hazard regression models. Results Follow-up interview was completed by 2,542 women (76.4?% of eligible patients). A diagnosis of hypertension was significantly associated with age, higher education (hazard ratio (HR) 0.54, CI 0.37-.79), baseline body mass index (BMI; ?0?kg/m2; HR, 1.90; CI, 1.24-.90), and trastuzumab medication (HR, 2.16; CI, 1.09-.33). An increased risk for CVD was associated with age, BMI, and intake of aromatase inhibitors (AI; HR, 1.42; CI, 1.09-.84). Risk of osteoporosis was also positively associated with AI treatment (HR, 2.15; CI, 1.64-.82) but inversely associated with a higher BMI (?0?kg/m2; HR, 0.50; CI, 0.31-.79). Conclusion In breast cancer survivors, treatment with AI constituted a risk factor for incident CVD and osteoporosis. Besides known risk factors, patients who were treated with trastuzumab may have an increased risk for hypertension. Implications for cancer survivors Reducing overweight and regular sport/cycling activities may help to prevent CVD after breast cancer. Patients should be monitored for risk factors and advised on possible cardiac side effects of AI and trastuzumab.